For example, in patients with advanced pancreatic cancer (NCT02767557), the addition of tocilizumab (an anti-IL-6R antibody) to gemcitabine/nab-paclitaxel did not result in improved overall survival rate at 6 and 24 months, although more patients were alive at 18 months in the gemcitabine/nab-paclitaxel/tocilizumab group (100). Here, IL6R is linked to pancreatic neoplasm.